Imatinib (STI571)

Catalog No.S2475 Synonyms: CGP057148B, ST-1571

Imatinib (STI571) Chemical Structure

Molecular Weight(MW): 493.6

Imatinib (STI571) is a multi-target inhibitor of tyrosine kinase with inhibition for v-Abl, c-Kit and PDGFR, IC50 values are 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 35 Publications

6 Customer Reviews

  • Ba/F3-p210T315I cells were treated with indicated concentrations of imatinib with or without PDMP for 24 h. Apoptosis was determined as in A. Data are shown as percentage of sub-G1 for apoptosis in triplicate cultures. *P<0.05.

    FASEB J 2011 25, 3661-3673. Imatinib (STI571) purchased from Selleck.

    Targeting KITLG through c-KIT inhibition using Imatinib; one representative experiment is shown (n = 4).

    Oncotarget, 2016, 7(34):54583-54595. Imatinib (STI571) purchased from Selleck.

  •  

    Inhibition of thymidine (a and b) and cytarabine (c and d) uptake with imatinib. K562 cells (a and c) and MEG-01 cells (b and d) were incubated at 37 ◦C for 15 min with imatinib transport buffer, and then incubated with 0.5 Ci of [3H] thymidine or [3H] cytarabine for an additional 5 min in presence of imatinib. Cells were then washed 3 times, lysed and radioactivity associated to cell pellets was quantified. DMSO, dimethylsulfoxide; DPD, dipyridamole.

    Leukemia Res 2012 36, 1311-1314. Imatinib (STI571) purchased from Selleck.

    ZFX regulates imatinib sensitivity and PI3K/Akt signaling pathway in CML cells. Viability of cells transfected with si-ZFX at the indicated doses of imatinib for 24 h (a). Colonies of leukemia cells and imatinib-resistant cells transfected with si-ZFX following treatment with imatinib for 10 days (b). Western blot analysis of Akt, p-Akt, CyclinD1, CyclinE1, Bcl-2, and Caspase-3 in K562 and K562/G01 cells transfected with si-ZFX for 2 days (c). The relative densities of proteins were quantified and normalized to b-Actin (d). Values represented the mean ± SD data from experiments in triplicate. *P\0.05 and **P\0.01

    Cell Biochem Biophys, 2016, 74(2):277-83. Imatinib (STI571) purchased from Selleck.

  • Cell Viability assay results. A2C12, BetaD5, GammaA3, GammaD12, A549, CaCo2, HepG2 cell lines were treated with imatinib mesylate for 24h and 96h.

    Dr. Thomas Kruwel of Fraunhofer. Imatinib (STI571) purchased from Selleck.

    A. Viability curve for the c-Kit mutant MelMS melanoma cell line treated with increasing concentrations of imatinib for 72h (relative to DMSO-treated controls; mean ±sd; n=3) B. MelMS melanoma cells were treated with 50nM imatinib for 24h. The effects on c-Kit, ERK and AKT activation were determined by immunoblotting.

    Dr. Helen Rizos from the university of Sydney. Imatinib (STI571) purchased from Selleck.

Purity & Quality Control

Choose Selective PDGFR Inhibitors

Biological Activity

Description Imatinib (STI571) is a multi-target inhibitor of tyrosine kinase with inhibition for v-Abl, c-Kit and PDGFR, IC50 values are 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.
Targets
PDGFR [1]
(Cell-free assay)
c-Kit [2]
(M-07e cells)
v-Abl [1]
(Cell-free assay)
100 nM 100 nM 600 nM
In vitro

In vitro assays for inhibition of a panel of tyrosine and serine/threonine protein kinases show that Imatinib inhibits the v-Abl tyrosine kinase and PDGFR potently with an IC50 of 0.6 and 0.1 μM, respectively. [1] Imatinib inhibits the SLF-dependent activation of wild-type c-kit kinase activity with a IC50 for these effects of approximately 0.1 μM, which is similar to the concentration required for inhibition of PDGFR. [2] Imatinib exhibits growth-inhibitory activity on the human bronchial carcinoid cell line NCI-H727 and the human pancreatic carcinoid cell line BON-1 with an IC50 of 32.4 and 32.8 μM, respectively. [3] A recent study shows that Imatinib has the potential to exert its antileukemia effects in chronic myelogenous leukemia by down-regulating hERG1 K(+) channels, which are highly expressed in leukemia cells and appear of exceptional importance in favoring leukemogenesis. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LAMA-84 M13kVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HMUmlEPTB;MD6wO|MxPCEQvF2= MlrrV2FPT0WU
EM-2 NUfERlJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfLd4JxUUN3ME2wMlA5QDhizszN MonSV2FPT0WU
MEG-01 NVG2Ro1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4mwUWlEPTB;MD6wPFkzOSEQvF2= M1LUPXNCVkeHUh?=
BV-173 MnzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u2S2lEPTB;MD6xPFc1KM7:TR?= M3fVS3NCVkeHUh?=
K-562 NHnpOHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUL2XZV{UUN3ME2wMlIzPDN{IN88US=> MXrTRW5ITVJ?
CGTH-W-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrtXopKSzVyPUCuN|g{PzRizszN NFvPeJpUSU6JRWK=
ST486 NIGyXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TC[mlEPTB;MD62PFU1KM7:TR?= NWnk[HJmW0GQR1XS
NCI-H1436 MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwOUe4NFEh|ryP NGDlU2JUSU6JRWK=
NOS-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\zTWM2OD1zLk[1N|g{KM7:TR?= MlLsV2FPT0WU
A498 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTJwNUeyNlMh|ryP M2rXZXNCVkeHUh?=
BE-13 NVjRUmxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4L1[mlEPTB;Mj62NlExPiEQvF2= MWPTRW5ITVJ?
SUP-T1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fY[2lEPTB;Mz64NlkxPyEQvF2= M1rSPXNCVkeHUh?=
NCI-H1770 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTVwNUeyOlIh|ryP MnfKV2FPT0WU
IMR-5 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTZwMkKxOFch|ryP NUXNV|EyW0GQR1XS
LB2241-RCC M3rL[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzqR|ZZUUN3ME24MlA4Ozh2IN88US=> M2jUTnNCVkeHUh?=
TGBC24TKB MorDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRThwM{SwOVIh|ryP M{PLN3NCVkeHUh?=
SCC-15 Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3KZYR{UUN3ME2xNE44Pzh6IN88US=> MX;TRW5ITVJ?
BB49-HNC MoXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTF2LkOzN|Uh|ryP NHruZWFUSU6JRWK=
ES7 M2XXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fzS2lEPTB;MUSuO|M4QSEQvF2= NHfMTHpUSU6JRWK=
LB2518-MEL M3fsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS0[pJKSzVyPUG2MlYxQTRizszN NIXLV3VUSU6JRWK=
NCI-H510A NH7k[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzvcnA6UUN3ME2xO{4zPDR{IN88US=> MlTRV2FPT0WU
TE-441-T MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:wR4NKSzVyPUG3MlI5QDZizszN NFq3dZlUSU6JRWK=
HH MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLrTWM2OD1zNz6zPVk6KM7:TR?= MYDTRW5ITVJ?
LC4-1 NYDVOIVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33wbWlEPTB;MUiuNFY2OiEQvF2= NVm5NpZRW0GQR1XS
KARPAS-45 Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:3TWM2OD1zOD6xPFQ5KM7:TR?= NEjEWGpUSU6JRWK=
LB1047-RCC M2HhPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWexOpMxUUN3ME2xPE41PDV{IN88US=> MVrTRW5ITVJ?
NKM-1 NV3vR3A6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVniXWs2UUN3ME2xPU4{PTV{IN88US=> M{jUenNCVkeHUh?=
SCLC-21H M3jHcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DJfWlEPTB;MkCuNVI1PiEQvF2= M{TrcXNCVkeHUh?=
RS4-11 NHG4OGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJyLkOzNFgh|ryP NHHyXIRUSU6JRWK=
ALL-PO NGX6ZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrDe5RKSzVyPUKwMlgyPDlizszN NUj5[2JQW0GQR1XS
GDM-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3aTY1KSzVyPUKyMlU6PDVizszN NEfyRmNUSU6JRWK=
DMS-79 NF3qPGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJ2LkS5N|Qh|ryP NXTSclVUW0GQR1XS
MPP-89 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XXPGlEPTB;MkWuOlg4PCEQvF2= M3vaNHNCVkeHUh?=
NB10 M1vqfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGq0VHBKSzVyPUK2MlQ3QTlizszN NIj6bIdUSU6JRWK=
LS-513 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDZV5dXUUN3ME2yOk45QDR5IN88US=> MofQV2FPT0WU
L-540 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq0ZmRUUUN3ME2yOk46OTR|IN88US=> NGG2WHJUSU6JRWK=
ES1 M1jzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHP6[WVKSzVyPUK3MlUzOSEQvF2= MkftV2FPT0WU
NTERA-S-cl-D1 NES4R3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nQUmlEPTB;M{CuOVA6OyEQvF2= M3LsTHNCVkeHUh?=
EW-1 M2[2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\2TWM2OD1|Mj65OFU1KM7:TR?= MWnTRW5ITVJ?
Calu-6 M13BeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXSzcWN4UUN3ME2zN{4yQDV3IN88US=> MX7TRW5ITVJ?
CTV-1 NHnjXIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13UVWlEPTB;M{OuPVc5QSEQvF2= NGDWV2xUSU6JRWK=
YT MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLETWM2OD1|OD61NlA6KM7:TR?= NFvmZWVUSU6JRWK=
TE-6 NGfoUVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfjU3dKSzVyPUSxMlI4QThizszN M1XPVXNCVkeHUh?=
HT-144 NIC1VHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTRzLkW0PFYh|ryP MWfTRW5ITVJ?
EW-13 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTuTWM2OD12Mj6yO|kyKM7:TR?= MVjTRW5ITVJ?
KALS-1 NX3WSWRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjSTWM2OD12Mz6xN|I6KM7:TR?= MYPTRW5ITVJ?
MOLT-16 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jTeGlEPTB;NEWuNFc2OiEQvF2= M1fHcXNCVkeHUh?=
D-336MG MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDnTWM2OD12NT65OVk6KM7:TR?= NX\CPY02W0GQR1XS
TE-11 MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2K2dWlEPTB;NE[uOlU{KM7:TR?= MlHhV2FPT0WU
EB2 NYP3WoZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTR4Lk[5PUDPxE1? M3;lUnNCVkeHUh?=
SK-N-DZ NV;UUmR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\PbGJJUUN3ME20PE4xQTZzIN88US=> M2ji[3NCVkeHUh?=
SW684 M{PrPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVr3WpM5UUN3ME20PE4zPjl3IN88US=> MmjVV2FPT0WU
EW-18 M3X4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXyxbZNSUUN3ME20PE41Ozl3IN88US=> MlG1V2FPT0WU
RL95-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTVyLkC3NUDPxE1? NYLIRXdpW0GQR1XS
CHP-126 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;tRlV7UUN3ME21NE45QTB3IN88US=> M3[zcHNCVkeHUh?=
NCI-H1395 NInYeIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{G1dWlEPTB;NUGuO|g{PSEQvF2= NWrDe2d2W0GQR1XS
TE-15 NXHZRpZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TvT2lEPTB;NUKuNlU2PiEQvF2= NVS4PJlWW0GQR1XS
ES4 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTV{Lkm3O|Uh|ryP M4nnXXNCVkeHUh?=
TE-1 MlfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfVTWM2OD13Mz65OFU2KM7:TR?= MXHTRW5ITVJ?
SIMA NHrpWlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTV5LkOzNVEh|ryP NVLrSHlDW0GQR1XS
LB647-SCLC NHK2SXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTZ2LkGxPFgh|ryP MknVV2FPT0WU
KY821 MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTZ2LkK1OVIh|ryP NHmzfoZUSU6JRWK=
LC-2-ad M1TaWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLhTWM2OD14NT63OlAyKM7:TR?= MULTRW5ITVJ?
KP-N-RT-BM-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTZ4Lk[zOlYh|ryP M4fBXXNCVkeHUh?=
SW872 NI\tcGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2L1TWlEPTB;NkeuOFM5OiEQvF2= MkPnV2FPT0WU
ES5 NFexU4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTZ5Lk[5Olgh|ryP NYCxOXJCW0GQR1XS
SK-NEP-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTZ6LkO4NFMh|ryP MYfTRW5ITVJ?
RPMI-6666 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnvNnpQUUN3ME23NU4xOzJizszN NELuTmdUSU6JRWK=
UACC-812 NIDiWHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTdzLkG2NFkh|ryP M2TYNHNCVkeHUh?=
COLO-829 NEPBOpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTd{Lk[5PFch|ryP NILme3VUSU6JRWK=
KP-N-YS MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGe4Om9KSzVyPUeyMlcyOzlizszN MWXTRW5ITVJ?
GI-1 NV3uXlBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XUemlEPTB;N{OuNlg3QCEQvF2= MWjTRW5ITVJ?
ETK-1 NFLLT5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTd|LkS5N|Ih|ryP NVLJTFd2W0GQR1XS
LXF-289 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7zOm5iUUN3ME23N{44OjlizszN NFroe|lUSU6JRWK=
CAS-1 NGDEblRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLFTWM2OD15Mz64PFU4KM7:TR?= NInkUlFUSU6JRWK=
EW-22 MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVu1b4t7UUN3ME23OE44OTF3IN88US=> MkHlV2FPT0WU
NCI-H2196 M320dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTd3Lk[zO|kh|ryP NXPORZdqW0GQR1XS
EoL-1-cell NE\NVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7TTWM2OD16MT62PVY{KM7:TR?= NITLbo1USU6JRWK=
D-247MG MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofITWM2OD16Mj6wNlQ5KM7:TR?= M3PIW3NCVkeHUh?=
Becker NV6yNHlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTh{LkO0PFEh|ryP NYfES3BIW0GQR1XS
IST-MEL1 NXXZO2Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\6VWlEPTB;OEKuN|Q5OiEQvF2= NVHWRZFMW0GQR1XS
MDA-MB-134-VI M3PL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\GTWM2OD16Mj61PVk3KM7:TR?= MV3TRW5ITVJ?
NCI-H1092 MkLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT3NYx7UUN3ME24OE4xOTl5IN88US=> M4nV[3NCVkeHUh?=
KINGS-1 M1TXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnUTWM2OD16Nj6xOlE5KM7:TR?= MkjmV2FPT0WU
HCC2218 MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTEZo1wUUN3ME24Ok44QTF|IN88US=> MV;TRW5ITVJ?
GI-ME-N M2LJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHaPJlmUUN3ME24O{44Pjl7IN88US=> MkjzV2FPT0WU
AM-38 NEK1PI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTh6LkO5OVMh|ryP NVvGSlR7W0GQR1XS
KNS-42 NYj4PZJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXv4cWd{UUN3ME24PU4yODF6IN88US=> MmPNV2FPT0WU
C8166 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPNeWVWUUN3ME24PU43OTJ3IN88US=> MVXTRW5ITVJ?
Ramos-2G6-4C10 Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr6WnlPUUN3ME24PU45PzF7IN88US=> NF\xe2tUSU6JRWK=
CTB-1 NYDPN|ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXRS3prUUN3ME25NE43OzV5IN88US=> NYjoRWRYW0GQR1XS
HCE-4 NHX6eW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vZNWlEPTB;OUGuNVM{PiEQvF2= MWjTRW5ITVJ?
NCI-H526 NHP2XXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LRVmlEPTB;OUKuOFExOyEQvF2= NWfIT2VGW0GQR1XS
ECC4 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljMTWM2OD17ND6yOVU2KM7:TR?= NFrYUXVUSU6JRWK=
NCCIT M3fkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LrTWlEPTB;OUWuN|I6OiEQvF2= MXvTRW5ITVJ?
MZ7-mel NV7zT3pGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvXTWM2OD17NT65NFQh|ryP NVf6WZVDW0GQR1XS
COLO-684 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzhTWM2OD17Nj6yN|g2KM7:TR?= MVrTRW5ITVJ?
SU-DHL-1 MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vJcWlEPTB;OU[uPVg1OiEQvF2= MYDTRW5ITVJ?
SF126 M1\LN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7pTWM2OD17Nz61NlE4KM7:TR?= MYPTRW5ITVJ?
NMC-G1 NFnLfHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fidWlEPTB;OUiuOFU2PCEQvF2= NFSxSoNUSU6JRWK=
NB14 NX;P[HpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoGyTWM2OD17OD65NlA5KM7:TR?= NX74doNsW0GQR1XS
VA-ES-BJ MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HLZmlEPTB;OUmuOFA2PiEQvF2= NYq1[5lGW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Imatinib produces a different antitumor effect on three xenografted tumors derived from surgical samples of fresh human small cell lung cancers, with 80%, 40% and 78% growth inhibition of SCLC6, SCLC61 and SCLC108 tumors, respectively, and no significant inhibition of SCLC74 growth. [5] In high fat fed ApoE(-/-) mice, Imatinib significantly reduces the high fat-induced lipid staining area by 30%, 27% and 35% compared to high-fat diet untreated controls when dosed by gavage at 10, 20 and 40 mg/kg, respectively, and suppresses carotid artery lipid accumulation. [6]

Protocol

Kinase Assay:

[1]

+ Expand

PDGF receptor kinase activity:

PDGF receptor is immunoprecipitated from BALB/c 3T3 cell extracts with rabbit antiserum to the murine PDGF receptor for 2 hours on ice. Protein A-Sepharose beads are used to collect the antigen-antibody complexes. The immunoprecipitates are washed twice with TNET (50 mM Tris, pH 7.5, 140 mM NaCl, 5 mM EDTA, 1% Triton X-100), once with TNE (50 mM Tris, pH 7.5, 140 mM EDTA), and once with kinase buffer (20 mM Tris, pH 7.5,10 mM MgCl2). After stimulation with PDGF (50 ng/mL) for 10 minutes at 4 °C, different concentrations of drug are added to the reaction mixture. PDGF receptor kinase activity is determined by incubation with 10 μCi [7-33P]-ATP and l μM ATP for 10 minutes at 4 °C. Immune complexes are separated by SDS-PAGE on 7.5% gels.
Cell Research:

[3]

+ Expand
  • Cell lines: BON-1 cells and NCI-H727 cells
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method:

    BON-1 cells and NCI-H727 cells are seeded into flat-bottomed 96-well plates in triplicate and allowed to adhere overnight in 10% fetal bovine serum-supplemented DMEM or RPMI 1640 complete medium, respectively; the medium is then exchanged for serum-free medium (negative control) or serum-free medium containing serial dilutions of Imatinib. After 48 hours (control cultures do not reach confluence), the number of metabolically active cells is determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and absorbance is measured in a Packard Spectra microplate reader at 540 nm. Growth inhibition is calculated using the following formula: inhibition rate = (1 − a / b) × 100%, where a and b are the absorbance values of the treated and control groups, respectively.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: SCLC6, SCLC61, SCLC 74 and SCLC108 small cell lung cancers are injected into Swiss mice (nu/nu, female).
  • Formulation: Imatinib is diluted in water.
  • Dosages: 70 or 100 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 33 mg/mL (66.85 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 493.6
Formula

C29H31N7O

CAS No. 152459-95-5
Storage powder
in solvent
Synonyms CGP057148B, ST-1571

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03343600 Recruiting Patients Who Have Received Allo-HSCT National Taiwan University Hospital|Far Eastern Memorial Hospital|Tri-Service General Hospital|National Cheng-Kung University Hospital|Hualien Tzu Chi General Hospital November 9 2017 Phase 2
NCT00137111 Active not recruiting Lymphoblastic Leukemia Acute St. Jude Children''s Research Hospital|National Cancer Institute (NCI) July 8 2000 Phase 3
NCT01343173 Completed Chronic Myeloid Leukaemia University Hospital Bordeaux April 6 2011 Not Applicable
NCT03214718 Not yet recruiting Chronic Myeloid Leukemia Patients Assiut University August 5 2017 Not Applicable
NCT01319981 Active not recruiting Leukemia M.D. Anderson Cancer Center|Spectrum Pharmaceuticals Inc March 5 2013 Phase 2
NCT02812693 Withdrawn Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma Joanne Jeter|National Cancer Institute (NCI)|Merck Ltd.|Ohio State University Comprehensive Cancer Center November 4 2016 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you please advise whether it is a clear solution for compound dissolved in vehicle 2% DMSO+30% PEG 300+2% Tween 80+ddH2O?

  • Answer:

    For S2475 Imatinib (STI571), it is soluble in 2% DMSO+30% PEG 300+2% Tween 80+ddH2O at 2mg/ml. When making the solution, please dissolve the compound in DMSO clearly first. If it dissolves not readily, please sonicate and warm it in water bath at 45-50C. Then add PEG and Tween. After they mixed well, dilute with water.

  • Question 2:

    What is the difference between S2475 (Imatinib) and S1026 (Imatinib Mesylate)? Are they water soluble?

  • Answer:

    S2475 is free base of Imatinib while S1026 is a solt form of Imatinib. They have exactly the same biological activity but different solubility. S1026 can be dissolved in water, but S2475 is not soluble in water. S2475 can be dissolved in DMSO at up to 3mg/ml.

PDGFR Signaling Pathway Map

PDGFR Inhibitors with Unique Features

Related PDGFR Products

Tags: buy Imatinib (STI571) | Imatinib (STI571) supplier | purchase Imatinib (STI571) | Imatinib (STI571) cost | Imatinib (STI571) manufacturer | order Imatinib (STI571) | Imatinib (STI571) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID